Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	39.88	45.28	27.35	22.06	35.94
Short-Term Investments	79.23	172.29	164.07	32.07	39.08
Cash & Cash Equivalents	119.11	217.57	191.41	54.13	75.02
Cash Growth	-45.26%	13.67%	253.61%	-27.84%	-55.34%
Receivables	0.3	0.48	0.62	0.77	0.7
Other Current Assets	9.45	13.5	13	2.59	8.08
Total Current Assets	128.86	231.55	205.03	57.49	83.8
Property, Plant & Equipment	1.62	1.1	1.34	1.65	2.47
Long-Term Investments	62.77	12.24	34.24	0	0
Goodwill and Intangibles	0	6.97	7.05	7.12	7.2
Other Long-Term Assets	4.16	2.73	3.55	4.51	4.83
Total Long-Term Assets	68.55	23.05	46.18	13.29	14.49
Total Assets	197.41	254.6	251.21	70.78	98.3
Accounts Payable	8.88	10.35	9.99	5.25	9.92
Current Debt	0	0.68	0.69	0.6	0.64
Other Current Liabilities	22.07	10.9	12.25	9.02	11.88
Total Current Liabilities	30.95	21.94	22.93	14.87	22.43
Long-Term Debt	0	0	0	10.65	0
Other Long-Term Liabilities	9.27	35.04	30.94	7.61	5.95
Total Long-Term Liabilities	9.27	35.04	30.94	18.26	5.95
Total Liabilities	40.23	56.98	53.87	33.13	28.39
Total Debt	0	0.68	0.69	11.26	0.64
Debt Growth	-	-1.30%	-93.84%	1667.03%	-97.88%
Retained Earnings	-770.8	-682.32	-595.41	-504.54	-453.53
Comprehensive Income	-0.11	-0.9	-0.22	-0.09	-0.07
Shareholders' Equity	157.18	197.62	197.34	37.65	69.91
Net Cash / Debt	119.11	216.89	190.72	42.88	74.38
Net Cash / Debt Growth	-45.08%	13.72%	344.83%	-42.36%	-46.07%
Net Cash Per Share	1.71	3.33	3.36	1.01	1.80
Working Capital	97.9	209.61	182.1	42.62	61.37
Book Value Per Share	2.25	3.03	3.48	0.89	1.69

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).